Natera NTRA 深 沪
等待开盘 10-06 09:30:00 美东时间
425.64
+15.290
+3.73%
华盛通- 最 高427.4675
- 今 开410.71
- 成交量 199.99万股
- 最 低 316.00
- 昨 收 410.35
- 总市值 4099.50万
- 52周最高 427.4675
- 市盈率 静 --
- 换手率 2076.48%
- 52周最低 169.50
- 委 比 -90.32%
- 总股本 9.63万
- 历史最高 427.4675
- 量 比 1.14
- 振 幅 27.16%
- 历史最低 1.10
- 每 手 1
- 风险率 55.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Uber, Micron, Datadog And A Health Care Stock: CNBC’s ‘Final Trades’
CNBC’s Final Trades featured Uber, Micron, Natera and Datadog, with analysts citing bullish views and all four stocks posting gains.
09-22 20:24
Japan’s Pharmaceuticals And Medical Devices Agency Issues Regulatory Approval To Natera's Signatera Test
This approval supports the use of the Signatera test to guide adjuvant atezolizumab (Tecentriq®) treatment decisions in patients with MIBC. Natera expects to commercially launch Signatera for MIBC in Japan in the first
09-22 20:06
Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring
Tempus AI acquires Personalis for $1.5B to target the $20B MRD cancer monitoring market. Get full deal details and analysis.
07-22 02:52
Natera Partners With Aveta On Late-Stage Head And Neck Cancer Trial
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, and Aveta Biomics, Inc., a clinical-stage immuno-oncology company advancing first-in-class oral immunotherapies for solid tumors,
06-29 18:12
Natera Secures Landmark Japan Nod For Signatera In Colorectal Cancer
Natera won Japan approval for Signatera in colorectal cancer, paving the way for a commercial launch by 2026.
06-25 02:14
Natera Enhances Its Panorama Non-Invasive Prenatal Test, Adding Clinically-Validated Performance Data
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced a major enhancement to its Panorama non-invasive prenatal test (NIPT). Powered by the company's novel
05-26 18:09
Natera Positioned To Capture Growing $20 Billion MRD Opportunity-Analyst
William Blair starts Natera coverage, citing MRD growth potential, strong moat, and diversified pipeline supporting long-term outlook.
04-15 02:30
Judge Hands Natera 30% Ongoing Royalty In MRD Patent Battle
Natera rises after a Delaware court grants a 30% ongoing royalty in its MRD patent battle with ArcherDx and Invitae.
04-09 20:19
Natera's Signatera Data Suggests Select Breast Cancer Patients Could Skip Surgery
Natera Signatera data shows MRD-guided therapy may reduce surgery in older breast cancer patients; analysts maintain bullish outlook.
04-01 00:48
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
